MPN-MDS
US Focus Meeting 2026
📍 Downright Austin, A Renaissance Hotel, 701 E 11th St, Austin, TX 78701
🗓️ April 17 - 18, 2026
Last Year's Highlights
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the MPN-MDS Focus Meeting 2026, to be held on April 17 - 18, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing MPN-MDS research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Co-chairs of MPN-MDS US Focus Meeting 2026:
Prithviraj Bose, MD
MD Anderson Cancer Center, Houston, TX
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
aimee.williams@md-education.com
Agenda & Faculty
April 17, 2026 | Day 1
08:40 AM
JAK inhibitors for the treatment of Myelofibrosis – a Remarkable Journey
Ruben Mesa, MD
Atrium Health Levine Cancer Institute, Charlotte, NC
Session I: MPN and MDS: Bench to Clinic
Moderated by:
Andrew Dunbar, MD
MD Anderson Cancer Center, Houston, TX
Angela Fleischman, MD
University of California, Irvine Medical Center, Orange, CA
09:10 AM
Inflammation and the MDS
Angela Fleischman, MD
University of California, Irvine Medical Center, Orange, CA
09:30 AM
Inflammation and the MDS
Zhuoer Xie, MD
Moffitt Cancer Center, Tampa, FL
09:50 AM
Hitting Mutant JAK2 Harder - Preclinical Considerations
Andrew Dunbar, MD
MD Anderson Cancer Center, Houston, TX
10:10 AM
The Spectrum of Myeloid Neoplasm Abnormal Hematopoiesis
Michael R. Savona, MD
Vanderbilt University Medical Center, Nashville, TN
Session II: MPN and MDS Classifications and Risk Stratification
Moderated by:
Abdulraheem Yacoub, MD
University of Kansas Medical Center, Kansas City, KS
Maximilian Stahl, MD
Yale School of Medicine, New Haven, CT
11:10 AM
MPN Classification and Diagnosis
Carlos Bueso-Ramos, MD
MD Anderson Cancer Center, Houston, TX
11:30 AM
Prognostic Modeling in Myelofibrosis
Abdulraheem Yacoub, MD
University of Kansas Medical Center, Kansas City, KS
11:50 AM
State of the Art MDS Risk Stratification and Prognostication
Maximilian Stahl, MD
Yale School of Medicine, New Haven, CT
Session III: PV, ET and CML
Moderated by:
Lucia Masarova, MD
MD Anderson Cancer Center, Houston, TX
Marina Kremyanskaya, MD
Icahn School of Medicine at Mount Sinai, New York, NY
01:20 PM
Interferons Come of Age in PV and ET
Lucia Masarova, MD
MD Anderson Cancer Center, Houston, TX
01:40 PM
Hepcidin Modulation in PV
Marina Kremyanskaya, MD
Icahn School of Medicine at Mount Sinai, New York, NY
02:00 PM
JAK Inhibition For PV and ET - Lessons Learned
Pre-Recorded Talk
RR
Raajit K. Rampal, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
02:20 PM
How I Treat CML in 2026
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
Session IV: Myelofibrosis
Moderated by:
Prithviraj Bose, MD
MD Anderson Cancer Center, Houston, TX
03:10 PM
New Therapeutic Targets in MPNs
Stephen T. Oh, MD
Washington University School of Medicine, St. Louis, MO
03:30 PM
Developing New Drugs for Anemia of Myelofibrosis - Advances and Challenges
Prithviraj Bose, MD
MD Anderson Cancer Center, Houston, TX
03:50 PM
Aiming for Disease Modification in Myelofibrosis – New Drugs, New Endpoints?
Pankit Vachhani, MD
UAB Medicine, Birmingham, AL
04:10 PM
Targeting Mutant JAK2 and Mutant CALR for Therapeutic Benefit in Myelofibrosis
Naveen Pemmaraju, MD
MD Anderson Cancer Center, Houston, TX
April 18, 2026 | Day 2
08:10 AM
Restoring the Genome Guardian: Targeting TP53 Myeloid Neoplasm
David Sallman, MD
Moffitt Cancer Center, Tampa, FL
Session V: Atypical MPN and MDS/MPN
Moderated by:
Hussein Abbas, MD
MD Anderson Cancer Center, Houston, TX
Guillermo Montalban Bravo, MD
MD Anderson Cancer Center, Houston, TX
08:40 AM
Primer on Systemic Mastocytosis
Hussein Abbas, MD
MD Anderson Cancer Center, Houston, TX
09:00 AM
Primer on Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia
Hussein Abbas, MD
MD Anderson Cancer Center, Houston, TX
09:20 AM
CMML 2026 Updates
Guillermo Montalban Bravo, MD
MD Anderson Cancer Center, Houston, TX
09:40 AM
MDS/MPN Other Than CMML and CNL 2026 Updates
Guillermo Montalban Bravo, MD
MD Anderson Cancer Center, Houston, TX
Session VI: Lower Risk MDS
Moderated by:
Mikkael A. Sekeres, MD
University of Miami Miller School of Medicine, Miami, FL
10:40 AM
EMA for Lower Risk MDS: Luspatercept and Elritrecept
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL
11:00 AM
Telomerase Inhibition in LR-MDS
Yazan Madanat, MD
UT Southwestern Medical Center, Dallas, TX
11:20 AM
How I Sequence Therapies in LR-MDS
Mikkael A. Sekeres, MD
University of Miami Miller School of Medicine, Miami, FL
11:40 AM
Novel Agents in LR-MDS
Amy DeZern, MD
Johns Hopkins Medicine, Baltimore, MD
Session VII: Higher Risk MDS
Moderated by:
Amer Zeidan, MD
Yale School of Medicine, New Haven, CT
Debate: Verona Trial Ended the Dream in Higher Risk MDS to Move Beyond HMA
01:10 PM
No, Ventoclax is Still an Option
Guillermo Garcia-Manero, MD
MD Anderson Cancer Center, Houston, TX
01:30 PM
Yes, we Should Move Beyond Venetoclax
Sangeetha Venugopal, MD
University of Miami Miller School of Medicine, Miami, FL
01:50 PM
Novel Agents in Higher Risk MDS
Amer Zeidan, MD
Yale School of Medicine, New Haven, CT
02:10 PM
Taming the Bull Out of the Gate: Managing Secondary AML From MDS
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX
02:30 PM
MDS and AML Classification Coming Together in 2026
Sanam Loghavi, MD
MD Anderson Cancer Center, Houston, TX
Session VIII: AHSCT for MPN and MDS
Moderated by:
Jeanne Palmer, MD
Mayo Clinic, Cleveland, OH
Bart Scott, MD
Fred Hutchinson Cancer Center, Seattle, WA
03:20 PM
Transplant for Myelofibrosis
Jeanne Palmer, MD
Mayo Clinic, Cleveland, OH
03:40 PM
Transplant for MDS
Bart Scott, MD
Fred Hutchinson Cancer Center, Seattle, WA
04:00 PM
Maintenance Strategies Post AHSCT for MDS and MPN
Alain Mina, MD
Yale University School of Medicine, New Haven, CT
Rising stars in MDS and MPN
Moderated by:
Naveen Pemmaraju, MD
MD Anderson Cancer Center, Houston, TX
04:40 PM
Searching for the Definition of a Meaningful Response in MDS in 2026: Lower vs Higher Risk Definitions
Julie Braish, MD
Moffitt Cancer Center, Tampa, FL
05:00 PM
Treatment of Higher Risk MDS Prior to AHSCT: What Really Matters
Alex Bataller, MD
MD Anderson Cancer Center, Houston, TX
05:20 PM
Quest for Disease Modification in Myelofibrosis in the Era of Novel Agents & Combinations
Sankalp Arora, MD
MD Anderson Cancer Center, Houston, TX
05:40 PM
GLP-1 Agonists: Decreasing Inflammation and Possibly Disease Progression in MPNs: An Emerging Topic
Jennifer Marvin Peek, MD
MD Anderson Cancer Center, Houston, TX
Aimee Williams
Senior Project Manager
How long has Aimee Williams been in the business?
Aimee Williams has been with MD Education since 2022.
About Aimee Williams
I joined MD Education in 2022 as a Project Manager, leveraging my background in events management and passion for high-quality results. After earning a degree in Events Management, I gained hands-on experience managing projects while living in Nashville, TN. Driven and detail-oriented, I thrive in fast-paced environments, ensuring projects meet the highest standards. An avid traveler, I bring creativity and open-mindedness to problem-solving and client relationships.
